Prevalence of Barrett's esophagus in a Southern European country: a multicenter study.
Journal
European journal of gastroenterology & hepatology
ISSN: 1473-5687
Titre abrégé: Eur J Gastroenterol Hepatol
Pays: England
ID NLM: 9000874
Informations de publication
Date de publication:
01 12 2021
01 12 2021
Historique:
pubmed:
15
11
2021
medline:
12
4
2022
entrez:
14
11
2021
Statut:
ppublish
Résumé
Identification of Barrett's esophagus (BE) with the treatment of dysplasia is essential to prevent esophageal adenocarcinoma (EAC). Moreover, determination of BE prevalence is important to define subsequent management strategies. However, precise estimates on BE prevalence from several European countries are lacking. We aimed to determine BE prevalence in a Southern European country. A cross-sectional, multicenter study from November 2019 to February 2020 was performed defining BE as a columnar extent in the distal esophagus greater than or equal to 1 cm with intestinal metaplasia. A total of 1550 individuals, 51% male with a mean age of 62 (SD = 15) years undergoing upper endoscopy were included. The overall BE prevalence was 1.29% (95% confidence interval: 0.73-1.85); significantly higher in men [2.05% (1.06-3.04)] vs. women [0.53% (0.01-1.04)]. Of the 20 BE patients, eight were newly diagnosed and 12 were under surveillance. The median extent was C3 (min 0; max 16) M4.5 (min 2; max 16). One patient each had EAC (0.06%) and high-grade dysplasia (0.06%) at the time of endoscopy. There was no difference in prevalence between geographical regions, centers, use of sedation or experience of endoscopists. Considering all reports, 93% used standardized terminology, 23% accurate photodocumentation and 69% photodocumented the esophagogastric junction (EGJ). Furthermore, 80% used Prague classification, 55% Seattle protocol, 60% distance to the squamocolumnar junction, 75% to the EGJ and 40% to the hiatal pinch. When considering only reports with EGJ photodocumentation or Prague classification, the prevalence was 1.78% (0.91-2.64) or 1.03% (0.53-1.53). We report for the first time BE prevalence in Southern Europe and report a low overall prevalence in an unselected population. Future studies need to determine progression rates and how to improve quality metrics.
Sections du résumé
BACKGROUND
Identification of Barrett's esophagus (BE) with the treatment of dysplasia is essential to prevent esophageal adenocarcinoma (EAC). Moreover, determination of BE prevalence is important to define subsequent management strategies. However, precise estimates on BE prevalence from several European countries are lacking. We aimed to determine BE prevalence in a Southern European country.
METHODS
A cross-sectional, multicenter study from November 2019 to February 2020 was performed defining BE as a columnar extent in the distal esophagus greater than or equal to 1 cm with intestinal metaplasia.
RESULTS
A total of 1550 individuals, 51% male with a mean age of 62 (SD = 15) years undergoing upper endoscopy were included. The overall BE prevalence was 1.29% (95% confidence interval: 0.73-1.85); significantly higher in men [2.05% (1.06-3.04)] vs. women [0.53% (0.01-1.04)]. Of the 20 BE patients, eight were newly diagnosed and 12 were under surveillance. The median extent was C3 (min 0; max 16) M4.5 (min 2; max 16). One patient each had EAC (0.06%) and high-grade dysplasia (0.06%) at the time of endoscopy. There was no difference in prevalence between geographical regions, centers, use of sedation or experience of endoscopists. Considering all reports, 93% used standardized terminology, 23% accurate photodocumentation and 69% photodocumented the esophagogastric junction (EGJ). Furthermore, 80% used Prague classification, 55% Seattle protocol, 60% distance to the squamocolumnar junction, 75% to the EGJ and 40% to the hiatal pinch. When considering only reports with EGJ photodocumentation or Prague classification, the prevalence was 1.78% (0.91-2.64) or 1.03% (0.53-1.53).
CONCLUSION
We report for the first time BE prevalence in Southern Europe and report a low overall prevalence in an unselected population. Future studies need to determine progression rates and how to improve quality metrics.
Identifiants
pubmed: 34775458
doi: 10.1097/MEG.0000000000002315
pii: 00042737-202112001-00127
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e939-e943Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924–926.
Dubecz A, Gall I, Solymosi N, Schweigert M, Peters JH, Feith M, Stein HJ. Temporal trends in long-term survival and cure rates in esophageal cancer: a SEER database analysis. J Thorac Oncol 2012; 7:443–447.
Weusten B, Bisschops R, Coron E, Dinis-Ribeiro M, Dumonceau JM, Esteban JM, et al. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy 2017; 49:191–198.
Shaheen NJ, Falk GW, Iyer PG, Gerson LB; American College of Gastroenterology. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol 2016; 111:30–50.
Fitzgerald RC, di Pietro M, Ragunath K, Ang Y, Kang J-Y, Watson P, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut 2015; 63:47–42.
Spechler SJ, Prateek S, Souza RF, Inadomi JM, Shaheen NJ; American Gastroenterological Association. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology 2011; 140:1084–1091.
Qumseya B, Sultan S, Bain P, Jamil L, Jacobson B, Anandasababathy S, et al.; ASGE STANDARDS OF PRACTICE COMMITTEE. ASGE guideline on screening and surveillance of Barrett’s esophagus. Gastrointest Endosc 2019; 90:335–359.
Singh M, Gupta N, Gaddam S, Balasubramanian G, Wani S, Sinh P, et al. Practice patterns among U.S. gastroenterologists regarding endoscopic management of Barrett’s esophagus. Gastrointest Endosc 2013; 78:689–695.
Curvers WL, Peters FP, Elzer B, Schaap AJ, Baak LC, van Oijen A, et al. Quality of Barrett’s surveillance in The Netherlands: a standardized review of endoscopy and pathology reports. Eur J Gastroenterol Hepatol 2008; 20:601–607.
Marques de Sá I, Marcos P, Sharma P, Dinis-Ribeiro M. The global prevalence of Barrett’s esophagus: a systematic review of the published literature. United European Gastroenterol J 2020; 8:1086–1105.
Pereira AD, Chaves P. Low risk of adenocarcinoma and high-grade dysplasia in patients with non-dysplastic Barrett’s esophagus: results from a cohort from a country with low esophageal adenocarcinoma incidence. United European Gastroenterol J 2016; 4:343–352.
Bisschops R, Areia M, Coron E, Dobru D, Kaskas B, Kuvaev R, et al. Performance measures for upper gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. Endoscopy 2016; 48:843–864.
Beg S, Ragunath K, Wyman A, Banks M, Trudgill N, Pritchard DM, et al. Quality standards in upper gastrointestinal endoscopy: a position statement of the British Society of Gastroenterology (BSG) and Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland (AUGIS). Gut 2017; 66:1886–1899.
Instituto Nacional de Estatística. Instituto Nacional de Estatística; Statistics Portugal. viewed 13 December 2020. https://www.ine.pt/xportal/xmain?xpid=INE&xpgid=ine_indicadores&contecto=pi&indOcorrCod=0008273&selTab=tab0. [Accessed April 2021]
Branco MJ, Nogueira P, Contreiras T. Uma observação sobre a prevalência de algumas prevalência de algumas doenças crónicas em Portugal Continental. 2005.Repositório Instituto Nacional de Saúde Doutor Ricardo Jorge;
Kuipers EJ, Spaander MC. Natural history of Barrett’s esophagus. Dig Dis Sci 2018; 63:1997–2004.
Crews NR, Johnson ML, Schleck CD, Enders FT, Wongkeesong LM, Wang KK, et al. Prevalence and predictors of gastroesophageal reflux complications in community subjects. Dig Dis Sci 2016; 61:3221–3228.
Jacobson BC, Giovannucci EL, Fuchs CS. Smoking and Barrett’s esophagus in women who undergo upper endoscopy. Dig Dis Sci 2011; 56:1707–1717.
Jung KW, Talley NJ, Romero Y, Katzka DA, Schleck CD, Zinsmeister AR, et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett’s esophagus: a population-based study. Am J Gastroenterol 2011; 106:1447–1455.
Connor MJ, Weston AP, Mayo MS, Sharma P. The prevalence of Barrett’s esophagus and erosive esophagitis in patients undergoing upper endoscopy for dyspepsia in a VA population. Dig Dis Sci 2004; 49:920–924.
Pascarenco OD, Boeriu A, Mocan S, Pascarenco G, Drasoveanu S, Galeanu M, Dobru D. Barrett’s esophagus and intestinal metaplasia of gastric cardia: prevalence, clinical, endoscopic and histological features. J Gastrointestin Liver Dis 2014; 23:19–25.
Kuo CJ, Lin CH, Liu NJ, Wu RC, Tang JH, Cheng CL. Frequency and risk factors for Barrett’s esophagus in Taiwanese patients: a prospective study in a tertiary referral center. Dig Dis Sci 2010; 55:1337–1343.
Rex DK, Cummings OW, Shaw M, Cumings MD, Wong RK, Vasudeva RS, et al. Screening for Barrett’s esophagus in colonoscopy patients with and without heartburn. Gastroenterology 2003; 125:1670–1677.
Khoury JE, Chisholm S, Jamal MM, Palacio C, Pudhota S, Vega KJ. African Americans with Barrett’s esophagus are less likely to have dysplasia at biopsy. Dig Dis Sci 2012; 57:419–423.
Kula Z, Welshof A. The prevalence of Barrett’s oesophagus in own material of 6326 endoscopies. Gastroenterol Pol 2007; 14:85–89.
Elizondo JLH, Robles RM, Compean DG, Moreno EIG, Almaguer ODB, Garza HJM, González JAG. Prevalencia de esófago de Barrett: estudio observacional en una clínica de gastroenterología. Rev Gastroenterol Mex 2017; 82:296–300.
Kim JH, Rhee PL, Lee JH, Lee H, Choi YS, Son HJ, et al. Prevalence and risk factors of Barrett’s esophagus in Korea. J Gastroenterol Hepatol 2007; 22:908–912.
Zagari RM, Fuccio L, Wallander MA, Johansson S, Fiocca R, Casanova S, et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett’s oesophagus in the general population: the Loiano-Monghidoro study. Gut 2008; 57:1354–1359.
Zaninotto G, Avellini C, Barbazza R, Baruchello G, Battaglia G, Benedetti E, et al. Prevalence of intestinal metaplasia in the distal oesophagus, oesophagogastric junction and gastric cardia in symptomatic patients in north-east Italy: a prospective, descriptive survey. The Italian Ulcer Study Group ‘GISU’. Dig Liver Dis 2001; 33:316–321.
Gruppo Operativo per lo Studio delle Precancerosi dell’Esofago (GOSPE). Barrett’s esophagus: epidemiological and clinical results of a multicentric survey. Int J Cancer 1991; 48:364–368.
Robles SC, Peciña FS, Orta MDR. Barrett esophagus. An epidemiological study in an area of Spain. Rev Esp Enferm Dig 1995; 87:353–355.
Katsinelos P, Lazaraki G, Kountouras J, Chatzimavroudis G, Zavos C, Terzoudis S, et al. Prevalence of Barrett’s esophagus in Northern Greece: a prospective study (Barrett’s esophagus). Hippokratia 2013; 17:27–33.
Zagari RM, Eusebi LH, Galloro G, Rabitti S, Neri M, Pasquale L, Bazzoli F. Attending training courses on Barrett’s esophagus improves adherence to guidelines: a survey from the Italian Society of Digestive Endoscopy. Dig Dis Sci 2021; 66:2888–2896.
Vaughan TL, Fitzgerald RC. Precision prevention of oesophageal adenocarcinoma. Nat Rev Gastroenterol Hepatol 2015; 12:243–248.